Guidelines are advantageous, though not essential for improved survival among breast cancer patients

The purpose of this retrospective multicenter study was to resolve the pseudo-paradox that the clinical outcome of women affected by breast cancer has improved during the last 20 years irrespective of whether they were treated in accordance with clinical guidelines or not. This retrospective German...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2015-07, Vol.152 (2), p.357-366
Main Authors: Wolters, Regine, Wischhusen, Jörg, Stüber, Tanja, Weiss, Claire Rachel, Krockberger, Mathias, Bartmann, Catharina, Blettner, Maria, Janni, Wolfgang, Kreienberg, Rolf, Schwentner, Lukas, Novopashenny, Igor, Wischnewsky, Manfred, Wöckel, Achim, Diessner, Joachim
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Breast cancer
Breast Neoplasms - diagnosis
Breast Neoplasms - epidemiology
Breast Neoplasms - history
Breast Neoplasms - mortality
Breast Neoplasms - therapy
Cancer
Cancer patients
Cancer research
Cancer therapies
Care and treatment
Chemotherapy
Clinical outcomes
Clinical Trial
Endocrine therapy
Female
Germany - epidemiology
Guideline Adherence
Guidelines
History, 20th Century
History, 21st Century
Humans
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Grading
Neoplasm Staging
Oncology
Patient outcomes
Retrospective Studies
Risk Factors
Survival Analysis
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this retrospective multicenter study was to resolve the pseudo-paradox that the clinical outcome of women affected by breast cancer has improved during the last 20 years irrespective of whether they were treated in accordance with clinical guidelines or not. This retrospective German multicenter study included 9061 patients with primary breast cancer recruited from 1991 to 2009. We formed subgroups for the time intervals 1991–2000 (TI 1 ) and 2001–2009 (TI 2 ). In these subgroups, the risk of recurrence (RFS) and overall survival (OS) were compared between patients whose treatment was either 100 % guideline-conforming or, respectively, non-guideline-conforming. The clinical outcome of all patients significantly improved in TI 2 compared to TI 1 [RFS: p  
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-015-3484-2